Cargando…

Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China

About 10 million people in China are infected with hepatitis C virus (HCV), with the seroprevalence of anti-HCV in the general population estimated at 0.6%. Delaying effective treatment of chronic hepatitis C (CHC) is associated with liver disease progression, cirrhosis, hepatocellular carcinoma, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Qing, Xuan, Jian-Wei, Tang, Hong, Ye, Xiao-Guang, Xu, Peng, Lee, I-Heng, Hu, Shan-Lian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547290/ https://www.ncbi.nlm.nih.gov/pubmed/31183003 http://dx.doi.org/10.4254/wjh.v11.i5.421

Ejemplares similares

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Hepatitis C Virus in the Elderly in the Direct-Acting Antiviral Era: from Diagnosis to Cure
por: Mohammed Abdul, Mubeen Khan, et al.
Publicado: (2020)

Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals
por: Perez, Shira, et al.
Publicado: (2019)

Considering direct-acting antivirals to cure hepatitis C virus during pregnancy: is this the last treatment frontier?
por: Kushner, Tatyana, et al.
Publicado: (2019)

Achieving a hepatitis C cure: a qualitative exploration of the experiences and meanings of achieving a hepatitis C cure using the direct acting antivirals in Australia
por: Richmond, Jacqueline A., et al.
Publicado: (2018)

Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals
por: Prud’homme, Sylvie, et al.
Publicado: (2016)

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries
por: Barber, Melissa J., et al.
Publicado: (2020)

Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals
por: Gountas, Ilias, et al.
Publicado: (2019)

Economic evaluation of direct‐acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore
por: Wong, Yu‐Jun, et al.
Publicado: (2019)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
por: Martin, Natasha K., et al.
Publicado: (2016)

Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer
por: Kuromatsu, Ryoko, et al.
Publicado: (2022)

Long‐term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct‐acting antivirals
por: Ogawa, Eiichi, et al.
Publicado: (2021)

Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents
por: Hsu, Wei-Fan, et al.
Publicado: (2019)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection
por: Collins, Lauren F, et al.
Publicado: (2017)

Modeling how reversal of immune exhaustion elicits cure of chronic hepatitis C after the end of treatment with direct‐acting antiviral agents
por: Baral, Subhasish, et al.
Publicado: (2018)

Impact of All‐Oral Direct‐Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States
por: Park, Haesuk, et al.
Publicado: (2019)

Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China
por: Wang, Xiaozhong, et al.
Publicado: (2021)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

Characterizing Hepatitis C Virus–Specific CD4(+) T Cells Following Viral‐Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral Cure
por: Hartnell, Felicity, et al.
Publicado: (2020)

Direct-acting antivirals for acute hepatitis C in HIV-infected MSM
por: Millard, James Daniel, et al.
Publicado: (2016)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
por: Hill, Andrew, et al.
Publicado: (2018)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19
por: Kumar, Pramod, et al.
Publicado: (2021)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)

Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
por: John, Jason J., et al.
Publicado: (2021)

Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis
por: Zhang, Hang, et al.
Publicado: (2023)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Drug–Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C
por: Gao, Lu-Hua, et al.
Publicado: (2021)

Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021
por: Du, Xinyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rtfk49t22c1v9po450hh285eo4